CSL Opens Australian Biotechnology Manufacturing Facility

CSL Opens Australian Biotechnology Manufacturing Facility

Melbourne, Australia — 09/05/2014

CSL Limited today officially opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne.

The new world-class facility is located adjacent to CSL Behring’s manufacturing plant for plasma products and will play a key role in CSL’s global drug development strategy. It is one of the largest and most advanced facilities of its kind in Australia and will produce novel recombinant therapies on a large scale for international clinical trials.

Recombinant therapies are modified versions of naturally occurring human proteins that have been optimised to provide better treatment options for patients. CSL has more recently developed specialist capabilities in recombinant-based research, adding to its long-standing expertise in plasma protein therapeutics. The Company’s R&D pipeline currently includes recombinant therapies for a range of rare and serious disease, including bleeding disorders, inflammatory conditions and cancer.

The first therapy to be manufactured in the new biotech facility will be a novel blood clotting factor (rVIIa-FP) for the treatment of haemophilia. This is one of several longer-acting clotting factors being developed by CSL which aims to significantly reduce the number of injections required to maintain normal blood clotting in people with bleeding disorders. Clinical trials of rVIIa-FP in patients are expected to commence later this year in US, Europe and Australia.

The facility was officially opened by The Hon. Ian Macfarlane MP, Minister for Industry, The Hon. Denis Napthine MP, Premier of Victoria and The Hon. Gordon Rich-Phillips MLC, Minister for Technology, Victoria.

Speaking at the Opening, CSL’s CEO and Managing Director, Paul Perreault said “This world-class facility is key to the ongoing success of our global R&D strategy and reflects our commitment to provide better treatment options for people who suffer from bleeding disorders and other life-threatening conditions.”

“Outstanding Australian science was a key driver for CSL’s investment decision. It made sense to complement our excellent research capabilities here with the facilities to advance innovative science through to clinical trials.”

Strategic co-investment from the Australian and Victorian governments, announced in 2010 was instrumental in realising the project. The biotech facility is the centre-piece of a $257 million manufacturing expansion at the Broadmeadows site which will see it play an increasingly important role in CSL’s global operations. The total investment is expected to quadruple Broadmeadows’ manufacturing capacity and export potential by 2018 and generate more than 240 highly skilled jobs.

“We acknowledge both the Federal and Victorian Governments for helping to bring this world-class facility to fruition. It shows a strong commitment to the ongoing development of the biotechnology sector and advanced manufacturing as an important part of Australia’s future,” said Mr Perreault.

Mr Alain Weill, President of the World Federation of Haemophilia also took part in the opening ceremony. He is in Australia for the World Congress of Haemophilia, which gets underway in Melbourne on Sunday 11 May 2014.

“The ongoing development of new and improved therapies for haemophilia couldn’t be more important to the bleeding disorder community. It’s very heartening to see CSL working with governments in Australia to invest in new technologies and facilities that may benefit people with haemophilia all around the world.” said Mr Weill.


Interview opportunities Mr Paul Perreault – CEO & Managing Director, CSL Limited
Dr Andrew Cuthbertson – Chief Scientific Officer, CSL Limited

Media Contact: Jemimah Pentland, Senior Manager Communications, CSL Limited
P: +61 3 9389 1668 / +61 412 635 483 E: jemimah.pentland@csl.com.au.

Ida Fabiansson, Buchan Consulting
P: +612 9237 2811 / +61 421 287 661
E: ifabiansson@buchanwe.com.au.

Download this release: 
PDF icon CSL Opens Australian Biotechnology Manufacturing Facility (0.30Mb)

© 2017 CSL Limited